Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2020

View Archived Issues

Histamine H3 receptor agonist shows a protective role against cardiorenal damage in mice

Enrollment completed in phase Ib study of NF-kB decoy for chronic discogenic lumbar back pain

Novel RGC-specific AAV7m8-SIRT1 gene therapy shows neuroprotective effects in vivo

Biallelic variants in RALGAPA1 impact on neuronal function and brain development

Bristol-Myers Squibb discloses new protein-arginine deiminase type-4 inhibitors

Merck & Co., Idenix patent PRMT5 inhibitors

New USP28 and/or USP25 inhibitors identified at FORMA Therapeutics

Monoglyceride lipase inhibitors identified at Roche

Clinical data presented for hematopoietic stem cell therapy plus busulfan in patients with ART-SCID

Zhejiang Hisun Pharmaceutical synthesizes new IRAK-4 inhibitors

Finding the next pandemic threat early on

Anatomy study reveals schizophrenia subtypes

Visceral adipose inflammation found to be sex-specific

Biogen and Sangamo Therapeutics announce licensing collaboration agreement in neurology

Grant supports EnduRx's collaboration with MD Anderson on novel therapeutic for TNBC

Blue Earth begins phase III imaging study with rhPSMA 7.3 (18F) in newly diagnosed prostate cancer

miR-3197 and miR-2116-5p unveiled as biomarkers for diabetic retinopathy

Metabolomic study reveals biomarkers of polycystic ovary syndrome

Bolt Biotherapeutics begins first-in-human study of BDC-1001 in HER2 advanced tumors

Medivir announces phase Ia findings with MIV-818 in liver cancer

Favipiravir studied in clinical trials in China for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...